Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial.
Horiot JC, Bontemps P, van den Bogaert W, Le Fur R, van den Weijngaert D, Bolla M, Bernier J, Lusinchi A, Stuschke M, Lopez-Torrecilla J, Begg AC, Pierart M, Collette L. Horiot JC, et al. Radiother Oncol. 1997 Aug;44(2):111-21. doi: 10.1016/s0167-8140(97)00079-0. Radiother Oncol. 1997. PMID: 9288839 Clinical Trial.
The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects.
Van den Bogaert W, van der Schueren E, Horiot JC, De Vilhena M, Schraub S, Svoboda V, Arcangeli G, de Pauw M, Van Glabbeke M. Van den Bogaert W, et al. Among authors: horiot jc. Radiother Oncol. 1995 May;35(2):91-9. doi: 10.1016/0167-8140(95)01538-r. Radiother Oncol. 1995. PMID: 7569030 Clinical Trial.
[Hyperfractionated and accelerated radiotherapy in head and neck cancers: results of the EORTC trials and impact on clinical practice].
Horiot JC, Bontemps P, Begg AC, Le Fur R, Van den Bogaert W, Bolla M, N'Guyen T, Van den Weijngaert D, Bernier J, Lusinchi A, Stuschke D, Lopez Torrecilla D, Jancar B, Collette L, Van Glabbeke M, Pierart M. Horiot JC, et al. Bull Cancer Radiother. 1996;83(4):314-20. Bull Cancer Radiother. 1996. PMID: 9081333 Clinical Trial. French. No abstract available.
The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis.
Begg AC, Haustermans K, Hart AA, Dische S, Saunders M, Zackrisson B, Gustaffson H, Coucke P, Paschoud N, Hoyer M, Overgaard J, Antognoni P, Richetti A, Bourhis J, Bartelink H, Horiot JC, Corvo R, Giaretti W, Awwad H, Shouman T, Jouffroy T, Maciorowski Z, Dobrowsky W, Struikmans H, Wilson GD, et al. Begg AC, et al. Among authors: horiot jc. Radiother Oncol. 1999 Jan;50(1):13-23. doi: 10.1016/s0167-8140(98)00147-9. Radiother Oncol. 1999. PMID: 10225552 Free article.
Postoperative pelvic radiotherapy with or without elective irradiation of para-aortic nodes and liver in rectal cancer patients. A controlled clinical trial of the EORTC Radiotherapy Group.
Bosset JF, Horiot JC, Hamers HP, Cionini L, Bartelink H, Caspers R, Untereiner M, Ciambelloti E, Pierart M, Van Glabbeke M. Bosset JF, et al. Among authors: horiot jc. Radiother Oncol. 2001 Oct;61(1):7-13. doi: 10.1016/s0167-8140(01)00419-4. Radiother Oncol. 2001. PMID: 11578723 Clinical Trial.
Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882.
Antonini N, Jones H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, Fourquet A, Jager J, Hoogenraad W, Collette L, Pierart M, Hart G, Bartelink H. Antonini N, et al. Among authors: horiot jc. Radiother Oncol. 2007 Mar;82(3):265-71. doi: 10.1016/j.radonc.2006.09.014. Epub 2006 Nov 28. Radiother Oncol. 2007. PMID: 17126434 Clinical Trial.
201 results